IRELAND, March 5, 2018– Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the company, headquartered in Irvine, California, USA, has chosen the Mid-West of Ireland for the location of a new plant to manufacture delivery components for its transcatheter heart valve therapies. This new addition to Edwards’ global supply network, which includes a similar existing facility in the United States, will initially be configured to support the manufacturing of therapies that enable minimally invasive procedures on patients’ aortic, mitral and tricuspid valves, where open heart surgery would previously have been the norm.

“Today is a wonderful day as we mark this very significant regional investment. The arrival of Edwards Lifesciences is a vote of confidence in the Mid-West region as a destination for high-end medical technology manufacturers,” said Minister Heather Humphreys. “It will provide even more opportunities for local residents and communities to grow and thrive. My department, through the IDA, is committed to supporting Edwards as it establishes operations in Ireland and as the company continues to develop its innovative heart valve technologies.”

Added Pat Breen, Minister of State and TD for Clare, “On behalf of everyone in the Mid-West, I would like warmly welcome Edwards Lifesciences to the region. Their presence here serves to highlight the attractiveness of the region as a destination for progressive, innovation-driven companies. I would like to wish Edwards well in their future operations and assure them of our ongoing support.”

Edwards is planning to hire approximately 60 people this year in various functions, such as production staff, engineering and professional management, to work at its initial site located in the Shannon Free Zone.

The company plans to complete a new, purpose-built manufacturing facility in the Mid-West of Ireland in 2020. Once the facility is fully operational, the company expects it will employ approximately 600 people. Edwards’ investment in the project is expected to amount to approximately €80 million.

“The addition of a manufacturing location in Ireland is an element of Edwards’ global supply strategy to support future growth and reliability of supply, and continues the growth in employment Edwards has experienced both in the United States and around the world,” said Joe Nuzzolese, Edwards’ corporate vice president, global supply chain. “Choosing this location included many considerations, but an important one is a talented workforce with experience in medical technology. We look forward to becoming an integral part of the local community through engagement and philanthropic support, and providing educational and professional opportunities for our employees. We are excited to welcome these new associates into Edwards, with the shared goal of serving more patients around the world by delivering high quality life-saving technologies.”

The company expects to begin hiring new employees in Shannon by June. People interested in applying for a position can find out more information and submit applications at www.edwards.com/irelandjobs.

“This announcement by Edwards Lifesciences that it is establishing a new manufacturing facility in the Mid-West is terrific news for the region and for Ireland,” said Martin Shanahan, CEO of IDA Ireland. “The company’s arrival further enhances Ireland’s reputation as a preferred location for leading companies in the lifesciences sector. Winning investment for regional locations is a key focus for IDA Ireland and this project is an excellent one to secure for this region.” This project is supported by the government through IDA Ireland.

About Edwards Lifesciences

Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.edwards.com and follow us on Twitter @EdwardsLifesci.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements by Minister Humphreys, Minister Breen, Mr. Shanahan and Mr. Nuzzolese, and statements regarding expecting timing and scope of new manufacturing operations. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause the results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors including but not limited to unexpected changes or delays related to regulatory approvals, construction timing, scope of hiring, or other company dynamics. These factors are detailed in the company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2017. Our filings, along with important product safety information, are available at www.Edwards.com.

Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are property of their respective owners.